What drove AYA.AX stock higher today?

AYA.AX stock rose after Artrya reported first US revenue from its Salix coronary plaque module. Market reaction reflected proof of commercial demand. Trading volume was **206,036**, below the 50-day average, indicating selective buying interest.

What is Meyka AI’s price forecast for AYA.AX stock?

Meyka AI's forecast model projects **A$7.90** in 12 months for AYA.AX stock. This implies an upside of roughly **121.93%** from **A$3.56**. Forecasts are model-based projections and not guarantees.

How risky is investing in AYA.AX stock?

AYA.AX stock is higher risk due to negative earnings and high valuation ratios. Key risks include slow hospital adoption, reimbursement delays, and quarterly earnings volatility. Liquidity and short-term momentum can add trading risk.

Where can I get more details on Artrya and the news?

Find company details on Artrya’s site and the US revenue update via the MarketBeat summary. See the Artrya website [Artrya](https://www.artrya.com) and the MarketBeat report [MarketBeat / MSN](https://www.msn.com/en-au/money/).

AU Stocks

AYA.AX stock A$3.56 on ASX 11 Feb 2026: First US Salix revenue supports AI growth outlook

ByDanny Kontos February 11, 2026February 11, 2026

AYA.AX stock closed at A$3.56 on the ASX on 11 Feb 2026, up 4.40% on the day after the company reported initial US Salix revenue. Investors are watching Artrya Limited (AYA.AX) for signs that AI product sales can turn growth into durable revenue. Trading volume finished at 206,036 shares versus an average of 743,497, signalling measured interest. The company remains loss-making with EPS -0.18 and PE -19.33, so the market is pricing growth and execution over current profit metrics.